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Summary Up-regulation of autocrine motility factor receptor (AMF-R) expression has been shown to be
associated with invasion and metastasis of experimental tumour systems and human neoplasms. Monoclonal
antibodies against AMF-R (gp78) were used to stain 221 primary gastric cancer specimens, and level of
expression was examined in relation to pathological stage and prognostic values. In 125 out of 221 (56.6%)
patients, gp78 was detected. Expression of gp78 was associated with macroscopic type, lymphatic and venous
invasions, and lymph node and peritoneal metastasis. The level of gp78 expression in the cancer specimens was
associated with histopathological stage and grade of tumour penetration. Positive gp78 expression was
significantly associated with poor prognosis (P<0.001). This significant relationship remained among patients
in stages II and III. The results suggest that gp78 expression could be used as a prognostic marker in gastric
cancer patients.
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The incidence of gastric carcinoma is the highest of all
carcinomas, and it is the leading cause of death from cancer
in Japan. In spite of the improvement in surgical treatment
and chemotherapy, the prognosis in this disease is still poor
owing to local recurrence or metastasis (Baba et al., 1995;
Bonenkamp et al., 1995; Hallissey et al., 1994; Nakazato et
al., 1994).
Many investigators study the mechanism of tumour cell
invasion and metastasis to better understand local recurrence
and metastasis (Nekarda et al., 1994; Nomura et al., 1995;
Sato et al., 1994; Yonemura et al., 1995). Among the various
steps of invasion or metastasis of the cancer cell, cell motility
is one of the important factors that promotes cancer
progression (Fidler, 1990; Hart et al., 1989; Liotta et al.,
1986; Nabi et al., 1991). However, the relationship between
gastric cancer stages and cell motility-regulated factors has
not been reported. Thus, it is of obvious interest to study
such parameters in order to obtain an insight into the
biological behaviour of gastric cancers.
Autocrine motility factor (AMF) is a cytokine that is
produced and secreted by cancer cells and that stimulates
both random and directed cell migration through binding to
its receptor, a 78 kDa cell surface glycoprotein (gp78, AMF
receptor) (Liotta et al., 1986; Nabi et al., 1990, 1991; Silletti
et al., 1991). Recently, a molecular cloning of AMF receptor
(AMF-R) was reported (Watanabe et al., 1991a). Expression
of this receptor relates to cell motility-regulating effects and
also may play an important role in tumour cell invasion or
metastasis (Nabi et al., 1992; Watanabe et al., 1991b). Recent
studies have demonstrated that increased expression of gp78
is correlated with a high incidence of recurrence and
decreased survival of patients with colorectal cancer, bladder
cancer and oesophageal cancer (Nakamori et al., 1994; Otto
et al., 1994; Maruyama et al., 1995).
Here, we studied the expression of gp78 in specimens from
221 patients with primary gastric cancers. A possible
relationship between gp78 expression, clinicopathological
features and survival rates was examined in order to
establish the usage of this antigen for prognosis in human
primary gastric carcinoma.
Materials and Methods
Patients
Two hundred and twenty-one patients with primary gastric
cancer, who were diagnosed and treated at the Department of
Surgery II, Kanazawa University, from 1986 to 1991, were
evaluated retrospectively. All patients had undergone total or
subtotal gastrectomy combined with extensive lymph node
dissection. Throughout this report, the Japanese Classifica-
tion of Gastric Carcinoma by the Japanese Research Society
for Gastric Cancer was used for the description and
classification of variables. There were 139 men and 82
women. Their ages ranged from 28 to 88 years (mean +s.d.,
61.2 + 11.7 years). Histologically, there were 88 differentiated
adenocarcinomas (71 tubular adenocarcinomas and 17
papillary adenocarcinomas) and 133 undifferentiated adeno-
carcinomas (106 poorly differentiated adenocarcinomas, 12
mucinous adenocarcinomas and 15 signet-ring cell carcino-
mas). The tumour size ranged from 1.0 to 22.0 cm
(mean+s.d., 6.8+3.7 cm). Of the 221 patients, 186 (84.2%)
were positive for lymph node metastases, 22 (10.0%) were
positive for liver metastases, and 48 (21.7%) were positive for
peritoneal metastases. There were 50 patients with stage I, 49
with stage II, 39 with stage III and 83 with stage IV disease.
Immunohistochemical staining and evaluation
Sections (4 pm) from 10% formalin-fixed, paraffin-embedded
gastric carcinomas and adjacent normal gastric tissue were
deparaffinised. Endogenous peroxidase activity was blocked
by immersion in 0.3% hydrogen peroxide in methanol for
30 min. After rehydration and washing with phosphate-
buffered saline (PBS, pH 7.2), sections were incubated with
10% normal goat serum (Dako, Glostrup, Denmark) in PBS
for 20 min at room temperature to block non-specific binding
of the second antibody. After blocking against endogenous
avidin and biotin, sections were incubated with anti-gp78
monoclonal antibody, 3F3A (Nabi et al., 1990; Silletti et al.,
1991; Watanabe et al., 1991; Nakamori et al., 1994; Otto et
al., 1994; Maruyama et al., 1995), at a dilution of 1:200 in
PBS containing 1% bovine serum albumin (Sigma, St. Louis,
MO, USA) overnight at 4°C. After three rinses in PBS,
sections were incubated with biotinylated anti-rat immuno-
globulin (Dako) for 1 h at room temperature, washed three
times with PBS and reacted with streptoavidin-biotin system
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(Dako), using 0.04% 3,3'-diaminobenzide tetrahydrochloride
(Sigma) for 1 min as chromogen. Sections were lightly
counterstained in methyl green. Positive controls were
prepared using sections from formalin-fixed, paraffin-
embedded malignant melanoma. Negative controls were
prepared by substituting normal rat serum for the primary
antibody, which resulted in no staining.
The degree of monoclonal antibody reactivity with each
tissue sections was considered positive if unequivocal staining
of membrane or cytoplasm was seen in more than 10% of
tumour cells as described previously (Otto et al., 1994;
Maruyama et al., 1995). All sections were analysed blind
without knowledge of the patient's treatment outcome or
clinicopathological findings.
Statistical analysis
Statistical analyses were performed using the chi-square test.
Survival rate was calculated by the Kaplan-Meier method.
The outcomes of different groups of patients were compared
using the generalised Wilcoxon test. Using the Cox's
proportional hazard model, multivariate regression analysis
of survival data was performed (Cox, 1972). The difference
was considered to be significant when P was less than 0.05.
Results
A total of 221 gastric cancer specimens were stained for gp78
expression. There were 125 (56.6%) carcinomas positive for
gp78 expression. In tumour tissues, both cell membrane and
cytoplasm were immunohistochemically stained heteroge-
neously (Figure 1a and b). Weak staining of normal
mucosa, mainly in the proliferative zone, was also noticed
in some of the sections (Figure lc). Tumour cells stained
intensively were more often found in the invasive peripheral
region than in the central region of the tumour (Figure 2a
and b). There was no significant association between the gp78
expression and tumour size or histological type (Table I).
Infiltrating type tumours had more frequent evidence of
expression (68.0%) than localised type tumours (41.7%)
(P=0.0002). The depth of tumour penetration was such that
the gp78 expression was positive for 31.4%, 54.1% and
69.3% of patients in TI (m, sm), T2 (mp, ss) and T3,4 (se, si)
respectively. The difference between those three groups of
patients was statistically significant (P=0.0005). The
histopathological stage was such that the gp78 expression
was positive for 36.0%, 52.0%, 64.1% and 68.7% of patients
in stage I, II, III and IV respectively. There was a statistically
a
b
Figure 2 Tumour cells in the invasive front (arrows) were more
strongly stained for gp78 than those in the tumour centre. (a)
Lower magnification. Scale bar=250 m. (b) Higher magnifica-
tion. Scale bar- 100,um.
b c
Figure 1 Immunohistochemical staining of gp78 in human gastric tumour and mucosa tissues. (a) Well-differentiated
adenocarcinoma of the stomach. There is strong membrane and cytoplasmic immunostaining of the tumour cells. Scale
bar=50pm. (b) Poorly differentiated adenocarcinoma of the stomach. Only tumour cells were intensively stained for gp78. Scale
bar=50gum. (c) Normal mucosa tissue is showing weak immunoreactivity in epithelial cells. Scale bar=100um.Table I Correlation of gp78 expression and clinicopathological
findings
Variables gp78-negative gp78-positive P-valuea
Histological differentiation
Differentiated 43 45 0.2361
Undifferentiated 53 80
Macroscopic type
Localised 56 40 0.0002
Infiltrating 40 85
Depth of tumour penetration
m, sm 24 11
mp, ss 45 53 0.0005
se, si 27 61
Venous invasion
Negative 59 53 0.0075
Positive 37 72
Lymphatic invasion
Negative 24 11 0.0020
Positive 72 114
Lymph node metastasis
Negative 36 24 0.0040
Positive 60 101
Hepatic metastasis
Negative 88 111 0.6320
Positive 8 14
Peritoneal dissemination
Negative 86 87 0.0007
Positive 10 38
Histopathological stage
I 32 18
II 24 25 0.0018
III 14 25
IV 26 57
aChi-square test.
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Figure 3 Overall survival according to gp78 expression of
tumours in 221 patients with primary gastric cancer.
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Figure 4 Survival curves of 88 patients with primary gastric
cancer in stages II and III, subdivided according to gp78
expression of tumours.
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significant difference between these four groups of patients
(P=0.0018). The gp78 expression was also correlated with
both lymphatic invasion (P=0.0020) and venous invasion
(P=0.0075). The nodal status was such that gp78 staining
was found in 24 (40.0%) of 60 tumours without lymph node
involvement, and 101 (62.7%) of 161 tumours with lymph
node metastasis; there was a good correlation between these
two groups of tumours (P=0.0040). However, there was no
significant relationship between liver metastasis and gp78
expression. Eighty-seven (50.3%) of 173 tumours without
peritoneal dissemination were gp78 expression negative,
whereas 38 (79.8%) of 48 tumours with peritoneal
dissemination were positively stained for gp78; the difference
was statistically significant (P=0.0007). In all of the
examined cases, the patients with gp78 expression-positive
carcinomas had poorer prognoses than did the expression-
negative patients. The 5 year survival rates of the gp78
expression-positive group and the expression-negative group
were 37.5% and 63.8% respectively (Figure 3). There was a
significant advantage in survival for the gp78 expression-
negative group (P<0.001). Even when the patients who
belonged to early stage (stage I) or highly advanced stage
(stage IV) were excluded, the patients with gp78 expression-
positive tumours had a significantly poorer prognosis than
those with expression-negative tumours (P<0.05) (Figure 4).
In these groups (stages II and III), the 5 year survival rates of
the gp78 expression-positive group and the expression-
negative group were 59.3% and 75.3% respectively. In the
same group, the univariate analysis revealed no correlation
between prognosis and the other clinicopathological factors,
such as age, sex, tumour size, histological type, macroscopic
type, lymph node metastasis, serosal invasion, lymphatic
invasion and venous invasion (Table II). Multivariate
analysis also revealed that only gp78 expression was an
independent prognostic factor in all the clinicopathological
factors mentioned above (P=0.0388).
Discussion
Cell motility plays an important role in embryonic tissue
remodelling, wound healing, angiogenesis, immune defence,
invasion and metastasis. Cell locomotion is reported to be
affected by a variety of agents, including host-derived scatter
factor (Weidner et al., 1991), extracellular matrix components
(Turley et al., 1991) and various of the growth factors, such
as platelet-derived growth factor (Seppa et al., 1982),
fibroblast growth factor (Sato and Rifkin, 1988), insulin-like
growth factor (Stracke et al., 1989) and transforming growth
factor-fl (Mooradian et al., 1992). In normal physiological
status, motility is tightly regulated, whereas tumour cell
motility may be aberrantly regulated or autoregulated.
Tumour-secreted or autocrine factors, like AMF or auto-
taxin, may be involved in this autoregulation (Liotta et al.,
1986; Stracke et al., 1992). AMF receptor is also engaged in
tumour cell motility (Nabi et al., 1991, 1992; Watanabe et al.,
1991a). These studies mainly focus on the motility of
fibrosarcoma (Watanabe et al., 1991a; Watanabe et al.,
1994), fibroblast (Silletti and Raz, 1993) and melanoma cells
(Liotta et al., 1986; Silletti et al., 1991; Stracke et al., 1992).
A previous study reported the significant correlation
between gp78 expression and histological differentiation in
colorectal carcinoma (Nakamori et al., 1994). Here, we could
not find a significant relationship between gp78 expression
and histological differentiation in primary gastric carcinoma.
However, patients with undifferentiated type carcinomas had
higher positive rates of gp78 expression than patients with
differentiated type tumours. Correlation between cell motility
and cell differentiation is still unclear in gastric cancer. We
found that AMF-R expression was significantly correlated
with lymph node metastasis, extent of invasion and
lymphatic/venous invasion in primary gastric cancer, similar
to colorectal, oesophageal and bladder carcinomas. Further-
more, we found a new significant relationship between gp78AMF receptor in gastric cancer
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Table II Value of ten variables as prognostic factors of 88 patients with primary gastric cancer in stages II
and III, according to univariable and multivariable analysis of Cox's proportional hazard model
Univariate analysis Multivariate analysis
Variables Z-value P-value F-value P-value
Age
(<61 years/>61 years) 0.2887 0.7728 0.924 0.339
Sex
(male/female) 0.1368 0.9677 0.298 0.587
Tumour size
(<6 cm/>6 cm) 0.4035 0.6865 0.147 0.701
Histological differentiation
(Differentiated/undifferentiated) 0.2082 0.8350 0.716 0.400
Macroscopic type
(Localised/infiltrating) 0.3429 0.7316 0.002 0.964
Serosal invasion
(Positive/negative) 1.7089 0.0874 1.464 0.230
Venous invasion
(Negative/positive) 1.6201 0.1052 2.291 0.134
Lymphatic invasion
(Negative/positive) 0.6550 0.5124 0.121 0.728
Lymph node metastasis
(Negative/positive) 0.5009 0.6164 0.101 0.752
gp78 status
(Negative/positive) 2.3039 0.0212 4.431 0.039
expression and peritoneal dissemination in primary gastric
cancer. Peritoneal dissemination is one of the most frequently
encountered factors for non-curative resection. However, an
analysis of gp78 expression might be a useful indicator for
peritoneal dissemination in gastric cancer.
In this study, only gp78 expression was an independent
prognostic factor in all clinicopathological factors of the
stage II and III patients. Other factors, such as lymph node
metastasis, venous invasion, etc. did not appear to correlate
with prognosis in stages II and III. In Japan, we always
performed extended lymph node dissection at least at D2
level, sometimes at D4 level, for the curative resection of
advanced gastric cancer (Adachi et al., 1994; Yonemura et
al., 1991a,b; Aretxabala et al., 1987). We think the Japanese-
type extended lymphadenectomy might have an influence on
this result.
Patients in stage I have favourable prognoses with
adequate surgical treatments and mild chemotherapies
(Baba et al., 1995). Patients with stage II and III gastric
cancer can have hope that the disease could be cured with
completely extended radical dissection and adequate che-
motherapy (Maehara 1994; Nakazato et al., 1994). In
contrast, the prognoses of the patients in stage IV are poor,
in spite of extended surgical treatments and intensive
chemotherapies. Therefore, an analysis of gp78 expression
may provide additional guidance regarding post-operative
prognosis and the need for a chemotherapy regimen for each
patient. Furthermore, we previously reported the preopera-
tive evaluation of oncogene expression by reverse transcrip-
tion polymerase chain reaction (RT-PCR) with endoscopic
biopsy specimen for the assessment of malignant potential
(Ninomiya et al., 1992). It is suggested that if gp78 expression
is assessed by an endoscopic biopsy specimen before
operation, one may obtain an indication of the extent of
the tumour resection and the need for lymph node dissection.
We have demonstrated the use of continuous hyperthermic
peritoneal perfusion (CHPP) for therapy against peritoneal
dissemination in gastric cancer (Fujimura et al., 1990). With
an analysis of gp78 expression, CHPP could be carried out
only on the high-risk group.
Normal gastric mucosa, especially in the proliferative
zone, was positively stained with anti-gp78 antibody, but
more weakly than tumour cells in gastric cancer. In previous
studies, both normal colorectal mucosa and urothelial and
oesophageal epithelia were negatively stained for gp78
(Nakamori et al., 1994; Otto et al., 1994). AMF stimulates
motility of fibroblasts via its receptor, which might play an
important role in wound healing (Silletti and Raz, 1993).
Because gastric mucosa turns over rapidly, AMF receptor
might be involved in the migration of epithelial cells. Further
investigation is necessary to clarify the role of AMF and its
receptor in cellular migration within gastric mucosal grand.
We may conclude that the expression of AMF receptor
plays an important role in both the invasion and the
metastasis of gastric cancer cells and is involved in the
prognoses of patients with gastric cancer. An analysis of
AMF receptor may be useful in predicting the clinical
outcome and deciding the therapeutic schedule of patients
with carcinoma of the stomach.
Abbreviations
AMF, autocrine motility factor; AMF-R, AMF receptor; PBS,
phosphate-buffered saline; m, mucosa; sm, submucosa; mp,
muscularis propria; ss, subserosa; se, serosa-exposed; si, serosa-
infiltrating; gp78, 78 kDa cell surface glycoprotein; RT-PCR,
reverse transcription-polymerase chain reaction.
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